IGM Biosciences(IGMS) - 2022 Q3 - Quarterly Report

Financial Performance - The company reported a net loss of $168.5 million for the nine months ended September 30, 2022, compared to a net loss of $114.5 million for the same period in 2021, resulting in an accumulated deficit of $522.3 million as of September 30, 2022[113]. - Total operating expenses for the three months ended September 30, 2022, were $60.8 million, an increase of $16.6 million from $44.2 million in the same period of 2021[129]. - General and administrative expenses increased to $38.1 million for the nine months ended September 30, 2022, up from $26.8 million in 2021, representing an increase of $11.3 million[144]. - Research and development expenses rose to $134.3 million for the nine months ended September 30, 2022, compared to $87.9 million in 2021, an increase of $46.4 million[139]. - The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its research and development efforts[146]. Revenue and Collaboration - Collaboration revenue was $0.3 million for the three months ended September 30, 2022, attributed to the Sanofi Agreement, with no revenue recognized in the same period of 2021[130]. - Collaboration revenue was $0.7 million for the nine months ended September 30, 2022, attributed to the Sanofi Agreement, with no revenue recognized in the same period of 2021[137]. - The Sanofi Agreement includes a $150 million upfront payment and potential milestone payments exceeding $6 billion, with profit-sharing arrangements for oncology products[119]. Cash Flow and Financing - Net cash provided by operating activities was $32.0 million for the nine months ended September 30, 2022, compared to a net cash used of $89.7 million in 2021[154]. - Net cash used in investing activities was $206.8 million for the nine months ended September 30, 2022, primarily due to purchases of marketable securities[156]. - Net cash provided by financing activities was $218.9 million for the nine months ended September 30, 2022, mainly from the issuance of common stock in a public offering[158]. - The company completed a public offering in April 2022, raising approximately $218 million from the sale of 10 million shares of common stock[120]. Assets and Liabilities - As of September 30, 2022, the company had cash, cash equivalents, and marketable securities totaling $469.1 million, with an accumulated deficit of $522.3 million[147]. - As of September 30, 2022, the company held $469.1 million in cash, cash equivalents, and marketable securities, which included money market funds, U.S. Treasury securities, corporate bonds, commercial paper, and U.S. government agency securities[165]. - The company had no interest-bearing liabilities as of September 30, 2022, and historical fluctuations in interest rates have not been significant for its operations[165]. - An immediate 1% relative change in interest rates would not have a material effect on the fair market value of the company's cash equivalents and marketable securities[165]. Expenses and Future Outlook - Research and development expenses increased to $48.2 million for the three months ended September 30, 2022, up from $34.2 million in 2021, primarily due to advancements in clinical product candidates[131]. - Personnel-related expenses in research and development increased by $6.2 million, driven by additional headcount and stock compensation[133]. - The company expects significant increases in expenses and capital requirements as it advances clinical-stage product candidates and expands its pipeline[114]. - Future funding requirements will depend on various factors, including the costs associated with clinical trials and the need for additional capital to support product development[151]. Accounting and Compliance - The company did not have any off-balance sheet arrangements during the periods presented[161]. - There were no material changes to the company's critical accounting policies from those discussed in its Annual Report on Form 10-K filed on March 29, 2022[164]. - The company’s financial statements are prepared in accordance with U.S. GAAP, requiring estimates and assumptions that affect reported amounts of assets and liabilities[163]. - The primary objectives of the company's investment activities are to ensure liquidity and preserve capital, with exposure primarily to interest rate sensitivities[165]. - The company has the ability to hold its marketable securities until maturity, mitigating the impact of market interest rate changes on operating results[165]. - No recently adopted accounting pronouncements were reported by the company[162].